Browse the evidence

The dietary pattern of PCA-prudent was not significantly related to the odds of having CVD in T2D patients (adjusted OR: 0.93, 95% CI: 0.70–1.24).

This suggests that not all dietary patterns are equally associated with CVD risk, and practitioners should evaluate dietary recommendations accordingly.

Resistance training tempo has minimal overall effect on muscle hypertrophy.

Practitioners may consider that varying resistance training tempo may not significantly impact muscle growth.

Weight loss magnitude was lower in patients taking GLP-1 RAs compared to postbariatric patients (29.9 kg vs 47.2 kg).

Understanding the differences in weight loss can help tailor interventions for patients seeking body contouring.

Systematic measurement of sexual desire should be prioritized in future research on GLP-1 agonists.

Researchers should include sexual desire as a key outcome in studies involving GLP-1 agonists.

Gastrointestinal complaints were common but did not significantly influence satisfaction ratings or decisions to continue treatment.

Practitioners should note that while gastrointestinal side effects are common, they may not deter patients from continuing treatment if weight loss is achieved.

A modified prolactin-releasing peptide, NN501, reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia.

NN501 may be a viable alternative therapy for obesity management focusing on fatty acid oxidation.

Discontinuation rates for GLP-1 RAs can be up to 80% after 2 years.

Practitioners should be aware of high discontinuation rates when prescribing GLP-1 RAs.

LLM responses provided appropriate information about standard GLP1RA-related queries but lacked updated information on emerging concerns.

Practitioners should be aware that while LLMs can provide useful information, they may not reflect the latest developments in GLP1RA therapy.

Internet search responses were more heterogeneous and often commercially biased.

Practitioners should critically evaluate internet sources for GLP1RA information due to potential bias.

Meta-regression showed no significant effect modification by age, body mass index, HbA1c, follow-up duration, or sodium-glucose co-transporter 2 inhibitors use.

The effectiveness of semaglutide is consistent regardless of these common patient characteristics.

There were no significant differences in the amount of weight lost between semaglutide 0.5 mg and liraglutide 3 mg after 3 months.

Clinicians can expect similar weight loss outcomes from either treatment option.

Over half (60%) of participants with a BMI indicating obesity had no clinical diagnosis of obesity in their EHRs.

Clinicians should be aware that a significant number of patients with obesity may not be diagnosed, potentially leading to untreated health issues.

Men, and particularly NH-Asian men, may be at heightened risk of underdiagnosis of obesity.

Awareness of potential underdiagnosis in specific male populations can improve obesity management strategies.

There have been some adjustments in weight reduction medications available on the German market in the last two years.

Stay updated on the latest weight reduction medications available in Germany.

The article provides an outlook on new weight reduction medications that are about to be approved or are currently in Phase 3 of approval studies.

Be aware of new medications that may soon be available for weight reduction.

There are challenges to the use of GLP-1 RAs, including drug expense and availability.

Healthcare providers should be aware of the barriers to access when prescribing GLP-1 RAs.

The article provides an overview of available GLP-1 RAs, their mechanisms of action, indications, adverse reactions, and risks.

Providers can refer to this overview for practical information on GLP-1 RAs.

NHB participants reported higher perceived discrimination, sleep disturbance, and perceived stress than H and NHW participants at all time points.

Addressing psychosocial factors is crucial for improving surgical outcomes in NHB patients.

There may be a potential causal relationship between tirzepatide and vitreous hemorrhage in nondiabetic patients.

Caution is advised when prescribing tirzepatide, especially in nondiabetic patients.

A better healthcare provision for obesity treatment will initially burden the healthcare system but is expected to lead to a reduction in the obesity epidemic and cost savings in the long term.

Practitioners should prepare for initial challenges in the healthcare system while advocating for long-term benefits.

A broad societal consensus is crucial for implementing measures to reduce obesogenic living conditions.

Practitioners should engage with community efforts to create healthier environments.

Emerging clinical trials support the potential of GLP-1 receptor agonists in reversing cancer risk.

Practitioners should stay updated on clinical trial results regarding GLP-1 agonists and cancer risk.

Dietary supplements are generally safe, but their regulation is less stringent than for medicines.

Practitioners should ensure patients are aware of the regulatory status of dietary supplements.

A 10% energy surplus did not result in a significant change in body protein mass (0.00 kg; 95% CI, -0.38-0.39 kg; P = 0.980).

A modest increase in energy intake may not be sufficient to promote body protein mass gain.